- Home
- NAAS vs SILO Comparison
NAAS vs SILO Comparison
Compare NAAS & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- SILO
- Stock Information
- Founded
- NAAS 2019
- SILO 2010
- Country
- NAAS China
- SILO United States
- Employees
- NAAS N/A
- SILO N/A
- Industry
- NAAS Other Specialty Stores
- SILO Apparel
- Sector
- NAAS Consumer Discretionary
- SILO Consumer Discretionary
- Exchange
- NAAS Nasdaq
- SILO Nasdaq
- Market Cap
- NAAS 8.3M
- SILO 8.8M
- IPO Year
- NAAS 2017
- SILO N/A
- Fundamental
- Price
- NAAS $1.32
- SILO $0.52
- Analyst Decision
- NAAS
- SILO
- Analyst Count
- NAAS 0
- SILO 0
- Target Price
- NAAS N/A
- SILO N/A
- AVG Volume (30 Days)
- NAAS 1.3M
- SILO 561.7K
- Earning Date
- NAAS 05-27-2025
- SILO 05-09-2025
- Dividend Yield
- NAAS N/A
- SILO N/A
- EPS Growth
- NAAS N/A
- SILO N/A
- EPS
- NAAS N/A
- SILO N/A
- Revenue
- NAAS $43,258,393.00
- SILO $72,102.00
- Revenue This Year
- NAAS $19.53
- SILO $1.86
- Revenue Next Year
- NAAS $151.36
- SILO N/A
- P/E Ratio
- NAAS N/A
- SILO N/A
- Revenue Growth
- NAAS 50.34
- SILO N/A
- 52 Week Low
- NAAS $1.23
- SILO $0.72
- 52 Week High
- NAAS $76.80
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- NAAS 32.24
- SILO 31.21
- Support Level
- NAAS $1.18
- SILO $0.71
- Resistance Level
- NAAS $1.39
- SILO $1.13
- Average True Range (ATR)
- NAAS 0.24
- SILO 0.12
- MACD
- NAAS 0.07
- SILO -0.00
- Stochastic Oscillator
- NAAS 6.06
- SILO 5.96
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.